6. EVF prizes
American Venous Forum
Ovarian vein thrombosis (OVT) rarely occurs, so data on clinical presentation, natural history, and treatment outcomes are lacking. RD. Malgor and colleagues (USA) presented their own data in the lecture titled “The natural history and treatment outcomes of symptomatic ovarian vein thrombosis.” They examined 23 patients with symptomatic OVT (mean age, 44). The most frequent causes of OVT were postpartum depression and cancer, and the most frequent symptoms were abdominal and flank pain. Location was mostly on the right. Intravenous heparin leads to complete recanalization in 62% of patients and incomplete recanalization in 15% of patients, while 23% of veins remained occluded. Long-term follow-up (median of 27 months) revealed four recurrent deep vein thrombosis (DVT) and four deaths (all of them in cancer patients).
A. C. Ring and colleagues (USA) in the lecture “Enough of EMR based VTE risk scores – we need to implement VTE prophylaxis based on these alerts!” showed an effect of venous thromboembolism (VTE) prophylaxis with electronic medical records. With electronic alerts in 24 960 consecutive hospital patients, both surgical and medical, the VTE rate was 0.7% during the hospital stay.
American College of Phlebology
Awaited results of superglue treatment of saphenous reflux were presented by T. Proebstle (Germany). A 12-month follow-up of the European multicenter study on cyanoacrylate revealed that 92.9% of patients were free of reflux in the great saphenous vein in the legs. The superglue treatment was announced to be a slight killer of thermoablation due to no necessity to use anesthesia, no postprocedure compression, and no paraestesias. The ultrasound results are similar to thermoablation, the new method also has complications such as thrombophlebitis (11.4%), pain (8.6%), and thrombus extension to the deep vein (0.7%). Thus, it can be noted that no miracle happened. The new method must have more scientific support that takes into account its cost, which is evidently the highest of nearly all the competitive methods.
Japanese Society of Phlebology
Two very interesting and original topics were delivered by Japanese colleagues. In the first one by H. Ohmori (“Deep vein thrombosis in patients with severe motor and intellectual disabilities”), the very rare cohort of patients became a subject of investigation. Severely handicapped persons are usually not of interest to vascular specialists. Ohmori and colleagues examined 28 such patients (median age, 44.5) and found signs of a previous deep vein thrombosis in 12 of the patients. Another topic by N. Sakakibara (“Micropulsation as a key factor for endovenous pulsed laser ablation”) was experimental with the objective to observe the phenomenon of micropulsed laser emission in water and blood as a model of endovenous laser ablation.
